Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L

Yamaguchi, Julie; McArthur, Carole; Vallari, Ana; Sthreshley, Larry; Cloherty, Gavin A; Berg, Michael G; Rodgers, Mary A

Background: The full spectrum of HIV-1 diversity can be found in central Africa, including two divergent HIV-1 strains collected in 1983 and 1990 in Democratic Republic of Congo (DRC) that were preliminarily classified as group M subtype L. However, a third epidemiologically distinct subtype L genome must be identified to designate L as a true subtype.

Methods: Specimen CG-0018a-01 was collected in 2001 in DRC as part of an HIV prevention of mother to child transmission (PMTCT) study. Prior sub-genomic HIV-1 sequences from this specimen branched closely with proposed subtype L references. Metagenomic (mNGS) and HIV-specific target enriched (HIV-xGen) libraries were combined for next generation sequencing (NGS) to extend genome coverage. mNGS reads were analyzed for the presence of other co-infections with the SURPI bioinformatics pipeline.

Results: A complete HIV-1 genome was generated with an average coverage depth of 47,783x. After bioinformatic analysis also identified Hepatitis B virus (HBV) reads, a complete HBV genotype A genome was assembled with an average coverage depth of 73,830x. The CG-0018a-01 HIV-1 genome branched basal to the two previous putative subtype L strains with strong bootstrap support of 100. With no evidence of recombination present, the strain was classified as subtype L.

Conclusions: The CG-0018a-01 HIV-1 genome establishes subtype L and confirms ongoing transmission in DRC as recently as 2001. Since CG-0018a-01 is more closely related to an ancestral strain than to isolates from 1983 or 1990, additional strains are likely circulating in DRC and possibly elsewhere.

November 25, 2019
Year of publication
2019
Resource types
Journal and research articles
Tags
HIV-1 subtype L, HIV strains

Similar Resources

This study investigated whether oral pre-exposure prophylaxis (PrEP) alters timing and patterns of seroconversion when PrEP use continues after HIV-1 infection.

Medical male circumcision (MC) of HIV-infected men may increase plasma HIV viral load and place female partners at risk of infection. We assessed the effect of MC on plasma HIV viral load in HIV-infected men in Rakai, Uganda.

Introduction: At the epicentre of the HIV epidemic in southern Africa, adolescent girls and young women aged 15 -24 contribute a disproportionate 30% of all new infections and seroconvert 5 -7 years earlier than their male peers.

Efavirenz has become one of the most commonly used antiretroviral agents worldwide and is a component of WHO's recommended first-line antiretroviral therapy regimen.

To estimate the potential reduction in HIV incidence, we constructed a risk equation based on a flow diagram of the HIV cascade, linking HIV diagnosis and treatment coverage with estimates of annual incidence and prevalence. This was applied to numerous settings.

Final follow up of the HPTN 052 study of treatment as prevention shows no evidence of HIV transmission from people with fully suppressed viral load to their partners, four years after the first results from the study demonstrated that early HIV treatment reduced the risk of HIV transmission by…

Starting antiretroviral therapy (ART) significantly reduces the risk of tuberculosis (TB) for patients in South Africa, investigators report in the online edition of AIDS.

Objective

To assess the design, delivery and outcomes of interventions to improve adherence to treatment for paediatric tuberculosis in low- and middle-income countries and develop a contextual framework for such interventions.

Methods